Download the poster to learn how we integrate our high-diversity ATX-CLC mouse platform with Al/ML-driven optimization and high-throughput functional screening to accelerate the discovery of bispecifics.
Bispecific antibodies (bsAbs) have emerged as a powerful and versatile therapeutic modality for a variety of indications. By simultaneously binding two antigens or epitopes, bsAbs can redirect immune cells to tumor cells, circumvent drug resistance mechanisms, and enhance the specificity of target engagement.
However, their discovery is often complex, facing challenges like chain mispairing, potency, and developability. The integration of artificial intelligence (Al) and machine learning (ML) is helping overcome these hurdles, allowing for rational design and multi-parameter optimization to accelerate candidate selection.
Alloy Therapeutics leverages an integrated approach to bsAb discovery that combines their proprietary
ATX-CLC humanized common light chain mouse platform, VHH engineered synthetic libraries, AI/ML-driven engineering, and high-throughput functional screening methods to deliver potent, selective, and developable bispecifics.
Modular antibody discovery platforms enable the discovery of diverse common light chain (CLC) antibodies or single-domain VHH
antibodies-ideal building blocks for bispecific engineering.
Cutting-edge Al/ML tools analyze sequence and structural data to maximize candidate diversity and assess developability characteristics, enabling optimization early in the discovery workflow.
mAbForge™ delivers antibodies optimized for affinity, stability, solubility, specificity, immunogenicity, and more via design-build-test cycles and high-
throughput characterization.
